Feasibility study of temporary permanent pacemaker in patients with conduction block after TAVR.
LBBB
TAVR
atrioventricular block (AV block)
left bundle branch block
permanent pacemaker (PPM)
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
06
2022
accepted:
06
01
2023
entrez:
10
2
2023
pubmed:
11
2
2023
medline:
11
2
2023
Statut:
epublish
Résumé
Limited data exist on the use of temporary permanent pacemaker (TPPM) to reduce unnecessary PPM in patients with high-degree atrioventricular block (HAVB) after transcatheter aortic valve replacement (TAVR). This study aims to determine the feasibility of TPPM in patients with HAVB after TAVR to provide prolonged pacing as a bridge. One hundred and eleven consecutive patients undergoing TAVR were screened from August 2021 to June 2022. Patients with HAVB eligible for PPM were included. TPPM were used in these patients instead of conventional temporary pacing or early PPM. Patients were followed up for 1 month. Holter and pacemaker interrogation were used to determine whether to implant PPM. Twenty one patients met the inclusion criteria for TPPM, of which 14 patients were third-degree AVB, 1 patient was second-degree AVB, 6 patients were first degree AVB with PR interval > 240 ms and LBBB with QRS duration > 150 ms. TPPM were placed on the 21 patients for 35 ± 7 days. Among 15 patients with HAVB, 26.7% of them ( TPPM is reliable and safe in the small sample of patients with conduction block after TAVR to provide certain buffer time to distinguish whether a PPM is necessary. Future studies with larger sample are needed for further validation of the current results.
Sections du résumé
Background
UNASSIGNED
Limited data exist on the use of temporary permanent pacemaker (TPPM) to reduce unnecessary PPM in patients with high-degree atrioventricular block (HAVB) after transcatheter aortic valve replacement (TAVR).
Objectives
UNASSIGNED
This study aims to determine the feasibility of TPPM in patients with HAVB after TAVR to provide prolonged pacing as a bridge.
Materials and methods
UNASSIGNED
One hundred and eleven consecutive patients undergoing TAVR were screened from August 2021 to June 2022. Patients with HAVB eligible for PPM were included. TPPM were used in these patients instead of conventional temporary pacing or early PPM. Patients were followed up for 1 month. Holter and pacemaker interrogation were used to determine whether to implant PPM.
Results
UNASSIGNED
Twenty one patients met the inclusion criteria for TPPM, of which 14 patients were third-degree AVB, 1 patient was second-degree AVB, 6 patients were first degree AVB with PR interval > 240 ms and LBBB with QRS duration > 150 ms. TPPM were placed on the 21 patients for 35 ± 7 days. Among 15 patients with HAVB, 26.7% of them (
Conclusion
UNASSIGNED
TPPM is reliable and safe in the small sample of patients with conduction block after TAVR to provide certain buffer time to distinguish whether a PPM is necessary. Future studies with larger sample are needed for further validation of the current results.
Identifiants
pubmed: 36760563
doi: 10.3389/fcvm.2023.978394
pmc: PMC9905124
doi:
Types de publication
Journal Article
Langues
eng
Pagination
978394Informations de copyright
Copyright © 2023 Chang, Liu, Lu, Yao, Yin, Wu, Yuan, Luo, Liu, Yan, Zhang, Pu, Modine, Piazza, Jilaihawi, Jiang and Song.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Interv Card Electrophysiol. 2018 Jun;52(1):111-116
pubmed: 29532275
J Am Heart Assoc. 2019 Nov 5;8(21):e012594
pubmed: 31640455
Am J Cardiol. 2013 Nov 15;112(10):1632-4
pubmed: 23998348
Circulation. 2017 Sep 12;136(11):1049-1069
pubmed: 28893961
J Am Coll Cardiol. 2011 May 17;57(20):1988-99
pubmed: 21565636
Eur Heart J. 2013 Aug;34(29):2281-329
pubmed: 23801822
Cardiovasc Revasc Med. 2020 Jun;21(6):726-729
pubmed: 32171678
J Innov Card Rhythm Manag. 2019 May 15;10(5):3652-3661
pubmed: 32477730
JACC Cardiovasc Interv. 2018 Feb 12;11(3):301-310
pubmed: 29413244
JACC Cardiovasc Interv. 2016 Nov 14;9(21):2200-2209
pubmed: 27832845
EuroIntervention. 2019 Nov 20;15(10):875-883
pubmed: 31217147
Eur Heart J. 2021 Sep 14;42(35):3427-3520
pubmed: 34455430
Catheter Cardiovasc Interv. 2020 Apr 1;95(5):982-990
pubmed: 31037836
Am J Cardiol. 2006 Dec 15;98(12):1613-5
pubmed: 17145220
Circulation. 2009 Aug 4;120(5):e29-30
pubmed: 19652115
Europace. 2013 Sep;15(9):1287-91
pubmed: 23482613
Chest. 2019 Apr;155(4):749-757
pubmed: 30543806
JACC Cardiovasc Interv. 2021 Jan 25;14(2):115-134
pubmed: 33478630
J Cardiovasc Electrophysiol. 2021 May;32(5):1411-1420
pubmed: 33682218
J Am Coll Cardiol. 2020 Nov 17;76(20):2391-2411
pubmed: 33190683
JACC Cardiovasc Interv. 2022 Aug 22;15(16):1690-1692
pubmed: 35981849
Europace. 2020 Apr 1;22(4):515-549
pubmed: 31702000